Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 28, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day 120 List of Questions. The Day 120 List of Questions were issued by the Committee for Medicinal Products

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 22, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of the Company’s

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016. “In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline, for which we have retained significant North American rights, and our non-oncology pipeline, which

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 12, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco. A live webcast can be accessed by visiting the investors section of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.m., before the Honorable Denise J. Casper, United States Courthouse, Courtroom No. 11 of the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, Massachusetts 02210 in the matter of Karen J. van Ingen v. AVEO Pharmaceuticals, Inc., et al., Civil Action No. 1:14-cv-11672-DJC

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 6, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of

Download PDF –Phase 1/2 TiNivo Trial to Commence at the Institut Gustave Roussy in Paris- CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016. “The second quarter of 2016 marked a defining moment for AVEO, with the initiation of TIVO-3, our Phase 3 pivotal study of tivozanib in refractory advanced renal cell cancer, and the closing of debt and equity financings to